Identifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors
Clinical Science · 2024
DOI: 10.1042/cs20240537 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Science, 2024. Verfasst von Nicholas D Camarda und 21 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, U.S.A. Hauptthemen laut MEDLINE: Hypertension, Doxazosin, Endothelial Cells, Receptors, Vascular Endothelial Growth Factor. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, National Institutes of Health (NIH), NHGRI NIH HHS.
Abstract (Originalsprache)
Vascular endothelial growth factor receptor inhibitors (VEGFRis) improve cancer survival but are associated with treatment-limiting hypertension, often attributed to endothelial cell (EC) dysfunction. Using phosphoproteomic profiling of VEGFRi-treated ECs, drugs were screened for mitigators of VEGFRi-induced EC dysfunction and validated in primary aortic ECs, mice, and canine cancer patients. VEGFRi treatment significantly raised systolic blood pressure (SBP) and increased markers of endothelial and renal dysfunction in mice and canine cancer patients. α-Adrenergic-antagonists were identified as drugs that most oppose the VEGFRi proteomic signature. Doxazosin, one such α-antagonist, prevented EC dysfunction in murine, canine, and human aortic ECs. In mice with sorafenib-induced-hypertension, doxazosin mitigated EC dysfunction but not hypertension or glomerular endotheliosis, while lisinopril mitigated hypertension and glomerular endotheliosis without impacting EC function. Hence, reversing EC dysfunction was insufficient to mitigate VEGFRi-induced-hypertension in this mouse model. Canine cancer patients with VEGFRi-induced-hypertension were randomized to doxazosin or lisinopril and both agents significantly decreased SBP. The canine clinical trial supports safety and efficacy of doxazosin and lisinopril as antihypertensives for VEGFRi-induced-hypertension and the potential of trials in canines with spontaneous cancer to accelerate translation. The overall findings demonstrate the utility of phosphoproteomics to identify EC-protective agents to mitigate cardio-oncology side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, U.S.A.
- Genetics, Molecular, and Cellular Biology Program, Tufts Graduate School of Biomedical Sciences, Boston, MA, U.S.A.
- Tufts Cummings School of Veterinary Medicine, North Grafton, MA, U.S.A.
- Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, MA, U.S.A.
- Division of Hematology Oncology, Department of Medicine, Tufts Medical Center, Boston, MA, U.S.A.
- Broad Institute, Boston, MA, U.S.A.
ORCID-Profile: Nicholas D Camarda
Förderung
- NIH HHS
- National Institutes of Health (NIH)
- NHGRI NIH HHS
- NIGMS NIH HHS
- NCI NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Camarda, N. D., Lu, Q., Meola, D. M., Man, J. J., Song, Z., Travers, R. J., Lopez, K. E., Powers, S. N., Papanastasiou, M., DeRuff, K. C., Mullahoo, J., Egri, S. B., Davison, D., Sebastiani, P., Eblen, S. T., Buchsbaum, R., Huggins, G. S., London, C. A., Jaffe, J. D., …, & Jaffe, I. Z. (2024). Identifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors. Clinical Science. https://doi.org/10.1042/cs20240537
Vancouver
Camarda ND, Lu Q, Meola DM, Man JJ, Song Z, Travers RJ, et al. Identifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors. Clinical Science. 2024. doi:10.1042/cs20240537
BibTeX
@article{Camarda2024,
author = {Camarda, Nicholas D and Lu, Qing and Meola, Dawn M and Man, Joshua J and Song, Zeyuan and Travers, Richard J and Lopez, Katherine E and Powers, Sarah N and Papanastasiou, Malvina and DeRuff, Katherine C and Mullahoo, James and Egri, Shawn B and Davison, Desiree and Sebastiani, Paola and Eblen, Scott T and Buchsbaum, Rachel and Huggins, Gordon S and London, Cheryl A and Jaffe, Jacob D and Upshaw, Jenica N and Yang, Vicky K and Jaffe, Iris Z},
title = {Identifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors},
journal = {Clinical Science},
year = {2024},
doi = {10.1042/cs20240537}
}
EUVIMED